PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTretinoin
Tretinoin
Altreno, Atralin, Avita, Renova, Retin-a, Solage, Tretinoin, Tri-luma, Twyneo, Veltin, Ziana (tretinoin) is a small molecule pharmaceutical. Tretinoin was first approved as Retin-a on 1982-01-01. It is used to treat acne vulgaris, facial dermatoses, hyperpigmentation, and promyelocytic leukemia acute in the USA. The pharmaceutical is active against retinoic acid receptor gamma, retinoic acid receptor beta, and retinoic acid receptor alpha. In addition, it is known to target Nuclear receptor ROR-beta, nuclear receptor subfamily 2 group C member 2, nuclear receptor subfamily 2 group E member 1, and peroxisome proliferator-activated receptor delta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Altreno, Atralin, Avita, Renova, Retin-a, Tretinoin, Tretinoin microsphere (discontinued: Avita, Renova, Retin-a, Tretinoin, Vesanoid)
Combinations
Clindamycin tretinoin, Tri-luma, Twyneo, Veltin, Ziana (discontinued: Solage)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tretinoin
Tradename
Company
Number
Date
Products
RETIN-ABausch Health CompaniesN-017955 RX1982-01-01
1 products, RLD, RS
RETIN-ABausch Health CompaniesN-019049 RX1988-09-16
1 products, RLD, RS
RETIN-A MICROBausch Health CompaniesN-020475 RX1997-02-07
2 products, RLD, RS
RETIN-A-MICROBausch Health CompaniesN-020475 RX2014-01-28
2 products, RLD, RS
ALTRENODow Pharmaceutical SciencesN-209353 RX2018-08-23
1 products, RLD, RS
ATRALINDow Pharmaceutical SciencesN-022070 RX2007-07-26
1 products, RLD, RS
AVITAMylanN-020404 RX1997-01-14
1 products
RETIN-ABausch Health CompaniesN-017522 RX1982-01-01
1 products, RLD, RS
RETIN-ABausch Health CompaniesN-017579 RX1982-01-01
1 products, RLD, RS
RENOVABausch Health CompaniesN-021108 RX2000-08-31
1 products, RLD, RS
Show 1 marketed
Show 4 discontinued
Mequinol
+
Tretinoin
Tradename
Company
Number
Date
Products
SOLAGEAlmirallN-020922 DISCN1999-12-10
1 products
Hide discontinued
Clindamycin phosphate
+
Tretinoin
Tradename
Company
Number
Date
Products
VELTINAlmirallN-050803 RX2010-07-16
1 products, RLD, RS
ZIANABausch Health CompaniesN-050802 RX2006-11-07
1 products, RLD, RS
Fluocinolone acetonide
+
Hydroquinone
+
Tretinoin
Tradename
Company
Number
Date
Products
TRI-LUMAGaldermaN-021112 RX2002-01-18
1 products, RLD, RS
Benzoyl peroxide
+
Tretinoin
Tradename
Company
Number
Date
Products
TWYNEOMayne GroupN-214902 RX2021-07-26
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
011010 niacinamide 4% / tretinoin 0.025%unapproved drug other2020-07-02
011013 niacinamide 4% / tretinoin 0.025%unapproved drug other2020-07-02
011020 niacinamide 4% / tretinoin 0.05%unapproved drug other2020-07-02
011021 niacinamide 4% / tretinoin 0.05%unapproved drug other2020-07-02
011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025%unapproved drug other2020-07-02
011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05%unapproved drug other2020-07-02
141016 hydrocortisone 0.5% / hydroquinone 4% / tretinoin 0.025%unapproved drug other2020-07-02
141017 hydrocortisone 0.5% / hydroquinone 6% / tretinoin 0.025%unapproved drug other2020-07-02
141060 hydrocortisone 0.5% / hydroquinone 4% / tretinoin 0.025%unapproved drug other2020-07-02
141061 hydrocortisone 0.5% / hydroquinone 8% / tretinoin 0.025%unapproved drug other2020-07-02
Show 85 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acne vulgarisEFO_0003894D000152L70
promyelocytic leukemia acute—D015473C92.4
facial dermatoses—D005148—
hyperpigmentation—D017495—
lentigo—D007911L81.4
toxoplasmosisEFO_0007517D014123B58
bacterial infections—D001424A49
streptococcal infectionsEFO_1001476D013290—
bacterial vaginosisEFO_0003932D016585—
pneumocystis pneumoniaEFO_0007448D011020B59
Show 12 more
Agency Specific
FDA
EMA
Expiration
Code
BENZOYL PEROXIDE / TRETINOIN, TWYNEO, GALDERMA LABS LP
2024-07-26NC
Patent Expiration
Patent
Expires
Flag
FDA Information
Tretinoin, Altreno, Dow Pharm
106536562038-08-22DPU-2368
113247102038-08-22U-2368
Benzoyl Peroxide / Tretinoin, Twyneo, Galderma Labs Lp
104207432038-07-12U-3194
106538992030-12-30DPU-3194
110718782030-12-30DP
98681032028-08-08DPU-3194
86175802028-02-03DP
Fluocinolone Acetonide / Hydroquinone / Tretinoin, Tri-Luma, Galderma Labs Lp
79152432023-09-08DP
79395162023-09-08DP
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AD: Retinoids for topical use in acne
— D10AD01: Tretinoin
— D10AD51: Tretinoin, combinations
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XF: Retinoids for cancer treatment
— L01XF01: Tretinoin
HCPCS
Code
Description
S0117
Tretinoin, topical, 5 grams
Clinical
Clinical Trials
478 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C951222205658
Acne vulgarisD000152EFO_0003894L701161320552
Promyelocytic leukemia acuteD015473—C92.4317156645
ScabiesD012532—B8634112323
Lice infestationsD010373—B85.21262314
RecurrenceD012008——54—1211
MelanosisD008548EFO_0003963L81.11214411
Covid-19D000086382—U07.12621—10
MalariaD008288EFO_0001068B54——1168
Skin agingD015595EFO_0005422——12148
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.0201710—341
NeuroblastomaD009447EFO_0000621—10209—238
Myelodysplastic syndromesD009190—D4614144——24
Myeloid leukemiaD007951—C92898—223
PreleukemiaD011289——593——13
SyndromeD013577——483——12
Lung neoplasmsD008175—C34.90182——11
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3—53—18
Myeloproliferative disordersD009196—D47.1412——6
Non-small-cell lung carcinomaD002289——141——6
Show 44 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.087———11
NeoplasmsD009369—C8073——110
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.051——16
Breast neoplasmsD001943EFO_0003869C5022——26
Hodgkin diseaseD006689—C8134———6
LymphomaD008223—C85.934———6
Myelomonocytic leukemia juvenileD054429—C93.353———6
MelanomaD008545——46———6
Non-hodgkin lymphomaD008228—C85.942———5
Myelomonocytic leukemia chronicD015477—C93.142———5
Show 81 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—3————3
Acute diseaseD000208——1———12
Lymphoid leukemiaD007945—C911———12
B-cell chronic lymphocytic leukemiaD015451—C91.12————2
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.22————2
Plasmablastic lymphomaD000069293—C83.32————2
Lymphomatoid granulomatosisD008230—C83.82————2
Major depressive disorderD003865EFO_0003761F221———12
Congenital abnormalitiesD000013EFO_0003915Q89.92————2
Castration-resistant prostatic neoplasmsD064129——1————1
Show 31 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Erectile dysfunctionD007172EFO_0004234F52.21————77
Vasculogenic impotenceD018783EFO_1001234—————55
Allergic rhinitisD065631—J30.9————22
RhinitisD012220EFO_0008521J31————22
Tick-borne diseasesD017282——————22
Tick bitesD064927——————22
Overactive urinary bladderD053201EFO_1000781N32.81————22
HemorrhoidsD006484EFO_0009552K64————22
RuptureD012421——————22
PigmentationD010858CHEBI_26130—————22
Show 50 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTretinoin
INNtretinoin
Description
All-trans-retinoic acid is a retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. It has a role as a keratolytic drug, an antineoplastic agent, an antioxidant, a signalling molecule, a retinoid X receptor agonist, an anti-inflammatory agent, an AP-1 antagonist, a retinoic acid receptor agonist and a human metabolite. It is a retinoic acid and a vitamin A. It is a conjugate acid of an all-trans-retinoate.
Classification
Small molecule
Drug classretinol derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Identifiers
PDB—
CAS-ID302-79-4
RxCUI—
ChEMBL IDCHEMBL38
ChEBI ID15367
PubChem CID444795
DrugBankDB00755
UNII ID5688UTC01R (ChemIDplus, GSRS)
Target
Agency Approved
RARB
RARB
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
5915
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
P10826
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Alternate
NR2C2
NR2C2
RXRA
RXRA
Organism
Homo sapiens
Gene name
NR2C2
Gene synonyms
TAK1, TR4
NCBI Gene ID
7182
Protein name
nuclear receptor subfamily 2 group C member 2
Protein synonyms
Nuclear hormone receptor TR4, Orphan nuclear receptor TAK1, Orphan nuclear receptor TR4, orphan receptor TR4, testicular nuclear receptor 4, Testicular receptor 4
Uniprot ID
P55092
Mouse ortholog
Nr2c2 (22026)
nuclear receptor subfamily 2 group C member 2 (P49117)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Tretinoin
+
Clindamycin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tretinoin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 255,534 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tretinoin, Vanrafia
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
97,459 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use